Tango Therapeutics price to sales ratio TNGX

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 73.1×
4-year median: 21.6×
Against its 4-year history: 95th; percentile: 0 is its lowest day, 100 its highest
4-year range: 2.9× to 80.2×
Peer median: 4.2×

Tango Therapeutics' price to sales ratio is 73.1× as of Oct 23, 2026.

That is above its 4-year median of 21.6×, higher than on 95% of days in the last 4 years.

Over that time it ranged from 2.9× in May 2025 to 80.2× in Aug 2026.

The median for 10 large drugmakers of a similar size is 4.2×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	73.1×	18.1×	80.2×
2025	17.5×	2.9×	41.4×
2024	7.7×	7.3×	30.4×
2023	23.4×	10.6×	29.9×
2022	26.5×	12.5×	29.9×

Against its peers

Companies in Drug Manufacturers - General nearest Tango Therapeutics' size, closest first, today.

Company	Price to sales ratio
TNGXTango Therapeutics	73.1×
ARQTArcutis Biotherapeutics	8.5×
LQDALiquidia	8.5×
INDVIndivior Pharmaceuticals	3.1×
OGNOrganon	0.6×
NRIXNurix Therapeutics	3.9×
KNSAKiniksa Pharmaceuticals International	7.1×
LGNDLigand Pharmaceuticals	20.8×
AMRXAmneal Pharmaceuticals	2.1×
PBHPrestige Consumer Healthcare	2.0×
ALKSAlkermes plc.	4.4×
Peer median	4.2×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Tango Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.